Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.8B; returns 1 day -2.6%, 1 week +6.1%, 1 year +18.4%.

Trevi Therapeutics Inc. (TRVI) is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio™ (oral nalbuphine ER) for chronic cough in adults with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is an oral extended-release formulation of nalbuphine.

Groups TRVI belongs to

• Clinical Stage Biopharma
• Clinical Stage Biotech
• Biotechnology
• Healthcare
• Pharmaceuticals
• Rare Diseases

TRVI financial model: income statement, cash flow and balance sheet